KIOM-79 prevents apoptotic cell death and AGEs accumulation in retinas of diabetic db/db mice.
OBJECTIVE
KIOM-79 retards the development of diabetic nephropathy in animal models of type 1 and type 2 diabetes. In this study, we evaluated whether KIOM-79 could prevent apoptotic cell death and advanced glycation end products (AGEs) accumulation in the retinas of diabetic db/db mice.


METHODS
Mice were treated orally with KIOM-79 (150 mg/kg body weight) once daily for 12 weeks. Levels of retinal ganglion cell death were measured by terminal dUTP nick-end labeling (TUNEL) assay. In the retina, the activity of caspase-3 (a marker of apoptosis) and the formation of AGEs were measured by immunohistochemical staining.


RESULTS
KIOM-79 reduced the number of TUNEL-immunoreactive retinal cells. KIOM-79 attenuated caspase-3 expression and AGEs accumulation in the retina.


CONCLUSIONS
These data show that KIOM-79 can prevent apoptosis in neuronal cells, AGEs accumulation in the retina, and retard the development of diabetic retinopathy.
Sohn
Eun Jin
EJ
Department of Herbal Pharmaceutical Development, Korea Institute of Oriental Medicine, 461-24 Jeonmin-dong, Yuseong-gu, Daejeon 305-811, Republic of Korea.
Kim
Young Sook
YS
Kim
Chan-Sik
CS
Lee
Yun Mi
YM
Kim
Jin Sook
JS
D000284:Administration, Oral; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D053148:Caspase 3 / Q000378:metabolism; D016923:Cell Death / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D003930:Diabetic Retinopathy / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D004195:Disease Models, Animal; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors* / Q000378:metabolism; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use*; D012160:Retina / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D012165:Retinal Ganglion Cells / Q000378:metabolism / Q000473:pathology
D000975:Antioxidants; D017127:Glycation End Products, Advanced; C517978:KIOM 79; D010936:Plant Extracts; C505409:Casp3 protein, mouse; D053148:Caspase 3